Beneficial ownership — 13D / 13G
87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| Millennium Management LLC | UTZ Utz Brands, Inc. | 13G | 5.1% | Mar 22, 2024 | 2y |
| Heilbron Jack Kendrick | SQFT Presidio Property Trust, Inc. | 13D/A | 8.2% | Mar 22, 2024 | 2y |
| Southpoint Capital Advisors LP | MBLY Mobileye Global Inc. | 13G | 5% | Mar 20, 2024 | 2y |
| RA CAPITAL MANAGEMENT, L.P. | SERA Sera Prognostics, Inc. | 13G | 6.5% | Mar 20, 2024 | 2y |
| STEADFAST CAPITAL MANAGEMENT LP | SPR Spirit Aerosystems Holdings, Inc. | 13G | 5.5% | Mar 20, 2024 | 2y |
| Estate of Daniel L. Goodwin | BY Byline Bancorp, Inc. | 13G | 9.6% | Mar 11, 2024 | 2y |
| RS Fund LP | NURO NeuroMetrix, Inc. Common Stock | 13D/A | 9.9% | Feb 23, 2024 | 2y |
| Artal Participations S.a r.l | VIGL Vigil Neuroscience, Inc. Common Stock | 13G/A | 4.9% | Mar 29, 2024 | 2y |
| Bain Capital Life Sciences Fund II, L.P. | NUVL Nuvalent, Inc. | 13D/A | 4.1% | Mar 27, 2024 | 2y |
| Samsara BioCapital, L.P. | NKTX Nkarta, Inc. | 13D/A | 5.4% | Mar 27, 2024 | 2y |
| Leviticus Partners LP | ORN Orion Group Holdings Inc | 13G/A | 4.17% | Mar 27, 2024 | 2y |
| CAS Investment Partners, LLC | CDLX Cardlytics, Inc. | 13D/A | 14.4% | Mar 27, 2024 | 2y |
| James N. Topper | PBYI Puma Biotechnology, Inc. | 13G | 5.4% | Mar 25, 2024 | 2y |
| Carlyle Group Inc. | QTTB Q32 Bio Inc. | 13G | 9.2% | Mar 25, 2024 | 2y |
| STEPHEN FITZPATRICK | EVTL Vertical Aerospace Ltd. | 13D | 75.53% | Mar 22, 2024 | 2y |
| HCM Investor Holdings, LLC | MRNO Murano Global Investments Plc | 13D | 11% | Mar 20, 2024 | 2y |
| RA CAPITAL MANAGEMENT, L.P. | ANRO Alto Neuroscience, Inc. | 13G | 5.2% | Mar 19, 2024 | 2y |
| Lynx1 Capital Management LP | PASG Passage BIO, Inc. | 13G | 8.7% | Mar 19, 2024 | 2y |
| John Cotterell | DAVA Endava plc | 13G/A | 15.1% | Dec 31, 2023 | 2y |
| BAKER BROS. ADVISORS LP | IGMS IGM Biosciences, Inc. Common Stock | 13D/A | 12.4% | Mar 28, 2024 | 2y |
| SIT INVESTMENT ASSOCIATES INC | VPV Invesco Pennsylvania Value Municipal Income Trust | 13D | 9.9% | Mar 28, 2024 | 2y |
| SIT INVESTMENT ASSOCIATES INC | KTF Dws Municipal Income Trust | 13D/A | 14.59% | Mar 28, 2024 | 2y |
| SIT INVESTMENT ASSOCIATES INC | VTN Invesco Trust for Investment Grade New York Municipals | 13D | 8.28% | Mar 28, 2024 | 2y |
| Antofagasta plc | BVN Buenaventura Mining Co Inc | 13D/A | 18.9% | Mar 27, 2024 | 2y |
| New Enterprise Associates 15, L.P. | NKTX Nkarta, Inc. | 13D/A | 5.1% | Mar 27, 2024 | 2y |
| Venu Raman Kumar | AERT Aeries Technology, Inc. | 13D/A | 73.8% | Mar 26, 2024 | 2y |
| NOVO HOLDINGS A/S | SPRB Spruce Biosciences, Inc. | 13D/A | 3.9% | Mar 26, 2024 | 2y |
| PW Partners Atlas Fund IV LP | BJRI BJs RESTAURANTS INC | 13D/A | 5.4% | Mar 26, 2024 | 2y |
| Bhisham Khare | AERT Aeries Technology, Inc. | 13D | 9.83% | Mar 26, 2024 | 2y |
| LUO Jie | UXIN Uxin Ltd | 13D | 1.9% | Mar 26, 2024 | 2y |
| Michael Rapoport | HYFM Hydrofarm Holdings Group, Inc. | 13G | 5.1% | Mar 26, 2024 | 2y |
| Eve One Fund II L.P. | UXIN Uxin Ltd | 13D/A | 62.1% | Mar 26, 2024 | 2y |
| Timothy A. Springer | RNAC Cartesian Therapeutics, Inc. | 13D/A | 27.9% | Mar 26, 2024 | 2y |
| ORBIMED ADVISORS LLC | QTTB Q32 Bio Inc. | 13D | 18.9% | Mar 26, 2024 | 2y |
| Joy Capital Opportunity, L.P. | UXIN Uxin Ltd | 13D/A | 31.1% | Mar 26, 2024 | 2y |
| GSK plc | NKTX Nkarta, Inc. | 13D/A | 4.5% | Mar 25, 2024 | 2y |
| Radoff Bradley Louis | SPRB Spruce Biosciences, Inc. | 13G | 6.9% | Mar 22, 2024 | 2y |
| Alpha Wave Global, LP | LENZ LENZ Therapeutics, Inc. | 13G | 14.1% | Mar 21, 2024 | 2y |
| Elías Sacal Cababié | MRNO Murano Global Investments Plc | 13D | 87.2% | Mar 20, 2024 | 2y |
| Velan Capital Investment Management LP | OTLK Outlook Therapeutics, Inc. | 13G | 5.6% | Mar 18, 2024 | 2y |
| TANG CAPITAL MANAGEMENT, LLC | OTLK Outlook Therapeutics, Inc. | 13G | 9.99% | Mar 18, 2024 | 2y |
| BIGLARI CAPITAL CORP. | BH-A Biglari Holdings Inc. | 13D/A | 71.5% | Mar 15, 2024 | 2y |
| TLCW VENTURES PTE.LTD | WBUY Webuy Global Ltd | 13G | 11.98% | Jan 1, 2024 | 2y |
| AyurMaya Capital Management Company, LP | SLRN ACELYRIN, INC. Common Stock | 13G | 9.6% | Dec 31, 2023 | 2y |
| Vincent K. McMahon | TKO TKO Group Holdings, Inc. | 13G | 24.7% | Dec 31, 2023 | 2y |
| Omni Retail Enterprises, LLC 1 | WHLM Wilhelmina International, Inc. | 13G | 18.4% | Dec 29, 2023 | 2y |
| Impact Prosperity Partners, LLC, as Agent 1 | WHLM Wilhelmina International, Inc. | 13G/A | 0% | Dec 29, 2023 | 2y |
| Harraden Circle Investments, LLC | PFSA Profusa, Inc. | 13G | 5.04% | Mar 26, 2024 | 2y |
| Thomas J. Herzfeld, et al. | HERZ Herzfeld Credit Income Fund, Inc | 13D/A | 26.03% | Mar 25, 2024 | 2y |
| Fairmount Funds Management LLC | COGT Cogent Biosciences, Inc. | 13D/A | 9.9% | Mar 25, 2024 | 2y |